A comprehensive global study led by Yale School of Public Health researchers has revealed that at least 20% of people living with dementia receive no care helping them with daily living, regardless of ...

An extended study after a primary trial supports using the anti-amyloid drug lecanemab (Leqembi) for up to 36 months in ...

A large natural experiment shows that the herpes zoster vaccine reduces dementia diagnoses by 20% over seven years. The ...

Receiving the live-attenuated zoster vaccine (Zostavax) reduced the probability of a new dementia diagnosis by 3.5 percentage ...